Correction to: Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial–mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2
Overexpressed miR-129-5p or silencing ZIC2 inhibits PCa cell migration and invasion. DU-145 cells were treated with miR-129-5p mimic, miR-129-5p inhibitor or/and si-ZIC2. a Cell migration within each group (× 200). b The migration cell number. c The cell invasion (× 200). d The invasive cell number in each group. *p < 0.05 vs. the blank and NC groups. The data are summarized as mean ± standard deviation and compared using one-way analysis of variance. The experiment was repeated three times and the average value was obtained
Fig. 7
Angiogenesis of PCa cells is blocked by overexpressed miR-129-5p or down-regulated ZIC2. DU-145 cells were treated with miR-129-5p mimic, miR-129-5p inhibitor or/and si-ZIC2. a The angiogenesis in each group; b the angiogenesis indexes in each group; c the protein expression of VEGF and CD31 in each group; d the statistical analysis of c. *p < 0.05 vs. the blank and NC groups. The data are summarized as mean ± standard deviation. The experiment was repeated three times and the data were compared using the one-way analysis of variance. VEGF vascular endothelial growth factor, GAPDH glyceraldehyde-3-phosphate dehydrogenase
×
×
Anzeige
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Correction to: Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial–mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2
verfasst von
Zhenming Jiang Yuxi Zhang Xi Chen Pingeng Wu Dong Chen
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
